Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

12.1K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.1K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

1
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
1
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

465
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
465
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.7K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.7K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.7K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

980
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
980

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Status of Alzheimer's and Parkinson's Disease Detections and Treatments.

ACS chemical neuroscience·2026
Same author

Thiosemicarbazone-Based Responsive MRI Contrast Agents Activated Through a Change in Cu<sup>II</sup> Binding Site on Albumin.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Dynamics of Aβ42 Tetramer by REST2-CHARMM36m Simulations.

The journal of physical chemistry. B·2026
Same author

Cationic Permethylated Cyclodextrins Capable of Self-Assembling Into Linear Nanostructures in Water.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

X-ray beam effects on metallo-peptides reflect redox events: insights from X-ray absorption spectroscopy measurements on metal complexes of truncated amyloid-β peptides.

Acta crystallographica. Section D, Structural biology·2026
Same author

A machine learning classifier to identify and prioritise genes associated with murine cardiac development.

PLoS genetics·2026

Related Experiment Video

Updated: Feb 13, 2026

Assaying &#946;-amyloid Toxicity using a Transgenic C. elegans Model
13:59

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model

Published on: October 9, 2010

26.7K

Amyloid-β/Drug Interactions from Computer Simulations and Cell-Based Assays.

Phuong H Nguyen1, Maria P Del Castillo-Frias2, Olivia Berthoumieux3

  • 1Laboratoire de Biochimie Théorique, UPR 9080 CNRS, Université Paris Diderot, Sorbonne Paris Cité, IBPC, Paris, France.

Journal of Alzheimer'S Disease : JAD
|March 23, 2018
PubMed
Summary

Targeting early amyloid-β (Aβ) oligomers shows promise for Alzheimer's disease (AD) drug development. This study uses simulations and experiments to understand how small molecules bind to Aβ peptides, aiding future drug design.

Keywords:
Alzheimer’s diseaseAβ oligomersall-atom/coarse-grained modelsamyloid simulationscell-based assaysdrugsin vitro studies

More Related Videos

SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

25.2K
Correlative Light and Electron Microscopy to Study Microglial Interactions with &#946;-Amyloid Plaques
10:52

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Published on: June 1, 2016

12.0K

Related Experiment Videos

Last Updated: Feb 13, 2026

Assaying &#946;-amyloid Toxicity using a Transgenic C. elegans Model
13:59

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model

Published on: October 9, 2010

26.7K
SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

25.2K
Correlative Light and Electron Microscopy to Study Microglial Interactions with &#946;-Amyloid Plaques
10:52

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Published on: June 1, 2016

12.0K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Computational Biology

Background:

  • Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the aggregation of amyloid-beta (Aβ) peptides.
  • Early oligomers of Aβ40 and Aβ42 are implicated as key toxic species in AD pathogenesis.
  • Developing therapeutic strategies targeting these early oligomers is a critical area of research.

Purpose of the Study:

  • To investigate the binding mechanisms of small molecules to Aβ40 and Aβ42 peptides.
  • To understand the interactions between potential drug candidates and toxic Aβ oligomers.
  • To provide insights for the rational design of more effective Alzheimer's disease therapeutics.

Main Methods:

  • Utilized extensive coarse-grained and all-atom molecular dynamics simulations.
  • Employed a variety of in vitro experimental techniques to validate simulation findings.
  • Integrated computational and experimental approaches to study drug-peptide interactions.

Main Results:

  • Detailed characterization of how small molecules interact with Aβ40 and Aβ42 oligomers.
  • Identification of specific binding modes and affinities relevant to therapeutic intervention.
  • Synergistic data from simulations and experiments provide a comprehensive view of molecular interactions.

Conclusions:

  • Understanding small molecule binding to Aβ oligomers is crucial for Alzheimer's disease drug discovery.
  • The combined simulation and experimental approach offers a powerful platform for evaluating drug candidates.
  • Future research should focus on leveraging these insights to design more potent and selective AD drugs.